Role of Hydrogen in Atherosclerotic Disease: From Bench to Bedside

Curr Pharm Des. 2021;27(5):713-722. doi: 10.2174/1381612826666201124112152.

Abstract

Atherosclerotic cardiovascular and cerebrovascular diseases are among the leading causes of morbidity and mortality worldwide. Given our recent understanding of its role as a small-molecule antioxidant and anti- inflammatory agent, hydrogen may play an important role in preventing and treating atherosclerotic cardiovascular and cerebrovascular disease. In the past decade, more than 50 publications in the English language literature considered the role of hydrogen as an anti-atherosclerotic agent. In this review, we summarized the pathophysiological characteristics and risk factors associated with atherosclerosis (AS) and the laboratory research data that focuses on hydrogen to prevent and treat this condition, including the responses observed in both animal models and human studies. We will also consider the molecular mechanisms underlying the efficacy of hydrogen molecules with respect to atherosclerotic disease. Future studies might include clinical trials with larger sample populations as well as experiments designed to explore the molecular mechanisms associated with hydrogen treatment in greater depth.

Keywords: Atherosclerosis; cardiovascular diseases; efficacy response; hydrogen; oxidative stress; prevention; treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Atherosclerosis* / drug therapy
  • Humans
  • Hydrogen* / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Hydrogen